Core Viewpoint - The study identifies AKR1B1 as a key regulatory enzyme in metabolic reprogramming and a potential biomarker and therapeutic target for hepatocellular carcinoma (HCC), suggesting that targeting AKR1B1 can reverse systemic therapy resistance in HCC [3][7]. Group 1: Research Findings - HCC is a major subtype of liver cancer and a leading cause of cancer-related deaths globally, with high incidence and mortality rates [2]. - The research team established HCC cell lines with multidrug resistance characteristics, observing enhanced metabolic activity in these cells [5]. - Multi-omics analysis revealed that glucose-lipid and glutathione metabolic pathways are overactive, playing critical roles in supporting tumor cell proliferation and survival [5]. Group 2: Mechanism of Resistance - The study constructed a metabolic reprogramming map for resistant HCC cells, identifying AKR1B1 as a key regulatory factor that maintains resistance by modulating energy metabolism and enhancing stress tolerance [5]. - The expression level of AKR1B1 is closely related to drug resistance and poor prognosis in HCC patients, highlighting its predictive value [5]. Group 3: Therapeutic Implications - The combination of Epalrestat, a clinically approved AKR1B1 inhibitor, with standard therapy (Lenvatinib) significantly alleviated resistance in HCC [7]. - The findings provide new insights into the mechanisms of resistance in HCC and lay the theoretical foundation for developing new predictive biomarkers and therapeutic strategies to overcome resistance [7].

Financial Performance - The company experienced significant fluctuations in revenue and profit due to various factors, including changes in the fair value of financial assets and a high base from the previous year's demand for flu treatment drugs [2][3]. - The price reductions from centralized procurement have led to substantial decreases in the prices of key products: Temozolomide decreased by 57%, Lenalidomide by nearly 70%, and the price of Oxaliplatin injection dropped by over 80% [4]. Future Outlook - The company anticipates an improvement in performance next year, as most products involved in national procurement are newly launched and should not face significant price declines [3][4]. - The company has several new products expected to be approved, which may contribute positively to future revenue [3]. R&D and Product Development - The company is focusing on innovative drug development, with several key products in clinical trials, including DT678 and PHP1003, which are expected to address significant medical needs [7]. - The company has increased its R&D investment, with over 60% of its 400+ R&D personnel holding master's degrees or higher [14]. Market Strategy - The company is expanding its overseas market presence, particularly in developing countries, with plans to enter the European and American markets [10]. - Recent products have been included in centralized procurement, which is expected to become a new profit growth point for the company [11]. Investment and Acquisitions - Currently, the company has no plans for refinancing or mergers and acquisitions [8]. - The company holds a 55.69% stake in Beijing New Mile Health Industry Group, which is expected to yield good returns in the future [5][6]. Regulatory and Competitive Landscape - The ongoing centralized procurement policy is likely to continue, but the extent of price reductions may stabilize, leading to a more rational market environment [4]. - The company is committed to increasing R&D investment despite recent performance challenges, aiming to enhance its competitive position in the industry [4].